| | | |   | | | | By Ed Silverman APStock "There are a number of states where the budgetary impact becomes impossible," said Rachel Sachs of the Washington University Law School. Read More | | By Damian Garde and Adam Feuerstein Ruby Wallau for STAT CEO Michel Vounatsos added that the company's decision to later slash the cost of the Alzheimer's therapy nearly in half was “courageous." Read More | | By Ed Silverman Adobe A new analysis finds changes to clinical trials – which can result in costly delays — are growing more common. Read More | | Sponsor content by Amgen How does a molecule go from discovery to development? Getting a medicine from the lab into the hands of patients doesn't come easily, as David Reese, Executive Vice President, Research and Development at Amgen, will tell you. "It takes more than a village — it takes an army that has worked for many years. That's why we're here, it's why I come to work every day." Hear from David, scientists, and researchers about what it takes to bring a molecule from discovery to development. | | By Rachel Cohrs Al Drago-Pool/Getty Images Becerra took the highly unusual step of ordering Medicare to reconsider historic premium hikes after Biogen cut the price of Aduhelm. Read More | | By Matthew Herper and Megan Molteni Adobe Bayer will pay Mammoth Biosciences $40 million to work on CRISPR-based gene-editing technologies in four different diseases. Read More | |
No comments